ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s stock price dropped 6.8% during mid-day trading on Monday . The stock traded as low as $3.13 and last traded at $3.22. Approximately 1,569,042 shares traded hands during trading, a decline of 76% from the average daily volume of 6,540,424 shares. The stock had previously closed at $3.45.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on IBRX shares. BTIG Research assumed coverage on ImmunityBio in a research report on Friday, January 10th. They issued a "buy" rating and a $6.00 price target for the company. D. Boral Capital reissued a "buy" rating and set a $30.00 price objective on shares of ImmunityBio in a research note on Monday, January 27th. Finally, EF Hutton Acquisition Co. I raised shares of ImmunityBio to a "strong-buy" rating in a report on Wednesday, October 23rd.
Read Our Latest Stock Analysis on ImmunityBio
ImmunityBio Price Performance
The firm's 50 day simple moving average is $3.18 and its two-hundred day simple moving average is $3.92. The firm has a market capitalization of $2.31 billion, a P/E ratio of -3.60 and a beta of 0.94.
Hedge Funds Weigh In On ImmunityBio
A number of large investors have recently bought and sold shares of the stock. State Street Corp raised its stake in shares of ImmunityBio by 10.1% during the third quarter. State Street Corp now owns 8,654,460 shares of the company's stock valued at $32,195,000 after acquiring an additional 790,408 shares during the last quarter. Barclays PLC raised its holdings in shares of ImmunityBio by 127.4% during the third quarter. Barclays PLC now owns 361,036 shares of the company's stock valued at $1,344,000 after acquiring an additional 202,248 shares in the last quarter. GSA Capital Partners LLP lifted its stake in ImmunityBio by 290.3% in the third quarter. GSA Capital Partners LLP now owns 107,985 shares of the company's stock worth $402,000 after acquiring an additional 80,318 shares during the period. XTX Topco Ltd boosted its holdings in ImmunityBio by 309.4% in the third quarter. XTX Topco Ltd now owns 92,910 shares of the company's stock valued at $346,000 after acquiring an additional 70,215 shares in the last quarter. Finally, Advantage Alpha Capital Partners LP purchased a new position in ImmunityBio during the 3rd quarter valued at $257,000. 8.58% of the stock is owned by hedge funds and other institutional investors.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
See Also
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
